Results 1 to 10 of about 864,255 (364)

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality [PDF]

Journal of the American Medical Association (JAMA), 2009
CONTEXT Circulating concentration of lipoprotein(a) (Lp[a]), a large glycoprotein attached to a low-density lipoprotein-like particle, may be associated with risk of coronary heart disease (CHD) and stroke. OBJECTIVE To assess the relationship of Lp(a)
The Emerging Risk Factors Collaboration
core   +2 more sources

Lipoprotein(a): the revenant [PDF]

European Heart Journal, 2017
In the mid-1990s, the days of lipoprotein(a) [Lp(a)] were numbered and many people would not have placed a bet on this lipid particle making it to the next century. However, genetic studies brought Lp(a) back to the front-stage after a Mendelian randomization approach used for the first time provided strong support for a causal role of high Lp(a ...
Erik S.G. Stroes, Baris Gencer, François Mach, Florian Kronenberg   +3 more
openaire   +4 more sources

Lipoprotein(a) [PDF]

MMW - Fortschritte der Medizin, 2021
AbstractLipoprotein(a) [Lp(a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, the LPA gene. The concentrations show a several-hundred-fold interindividual variability ranging from less than 0.1 mg/dL to more than 300 mg/dL.
openaire   +4 more sources

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

New England Journal of Medicine, 2022
BACKGROUND Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS We conducted a randomized, double-blind, placebo-controlled,
M. O’Donoghue, R. Rosenson, B. Gencer, J. A. López, N. Lepor, S. Baum, Elmer Stout, D. Gaudet, B. Knusel, J. Kuder, Xinhui Ran, S. Murphy, Hong Wang, You Wu, H. Kassahun, M. Sabatine   +15 more
semanticscholar   +1 more source

Lipoprotein (a): Recent Updates on a Unique Lipoprotein [PDF]

Current Atherosclerosis Reports, 2021
Genetic, epidemiological, and translational data indicate that Lipoprotein (a) [Lp(a)] is likely in the causal pathway for atherosclerotic cardiovascular diseases as well as calcification of the aortic valves.Lp(a) is structurally similar to low-density lipoprotein, but in addition to apolipoprotein B-100, it has a glycoprotein apolipoprotein(a) [apo(a)
Salim S. Virani, Salim S. Virani, Salim S. Virani, Sina Kinoush, Anum Saeed   +4 more
openaire   +2 more sources

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Elevated plasma levels of direct low‐density lipoprotein cholesterol (LDL‐C), small dense LDL‐C (sdLDL‐C), low‐density lipoprotein (LDL) triglycerides, triglycerides, triglyceride‐rich lipoprotein cholesterol, remnant lipoprotein particle ...
H. Ikezaki, E. Lim, L. Cupples, Ching‐Ti Liu, B. Asztalos, E. Schaefer   +5 more
semanticscholar   +1 more source

Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis

PLoS Medicine, 2020
Background Circulating lipoprotein lipids cause coronary heart disease (CHD). However, the precise way in which one or more lipoprotein lipid-related entities account for this relationship remains unclear.
T. Richardson, E. Sanderson, T. Palmer, M. Ala-Korpela, B. Ference, G. Davey Smith, M. Holmes   +6 more
semanticscholar   +1 more source

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

New England Journal of Medicine, 2020
BACKGROUND Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.
S. Tsimikas, E. Karwatowska-Prokopczuk, I. Gouni-Berthold, J. Tardif, S. Baum, E. Steinhagen-Thiessen, M. Shapiro, E. Stroes, P. Moriarty, B. Nordestgaard, S. Xia, J. Guerriero, N. Viney, L. O’Dea, J. Witztum   +14 more
semanticscholar   +1 more source

Statin therapy increases lipoprotein(a) levels.

European Heart Journal, 2020
AIMS Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect of statins on Lp(a) levels. METHODS AND RESULTS This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six ...
S. Tsimikas, P. Gordts, Chelsea L. Nora, C. Yeang, J. Witztum   +4 more
semanticscholar   +1 more source

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease

Arteriosclerosis, Thrombosis and Vascular Biology, 2020
Supplemental Digital Content is available in the text. Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In
A. Patel, Minxian Wang, J. Pirruccello, P. Ellinor, Kenney Ng, S. Kathiresan, A. Khera   +6 more
semanticscholar   +1 more source